Human Malarial Immunity And Assessment Of Emerging Artemisinin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$312,570.00
Summary
Resistance to antimalarial drugs is a major global threat for malaria treatment, control and elimination. Assessment of the spread of resistance is severely impeded by the presence of host immunity. This project will identify population biomarkers of immunity during antimalarial treatment to include in studies of antimalarial resistance. These findings will facilitate the correct assessment of the global spread of antimalarial resistance.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Determining The Mechanistic Basis Of The Patterns Of Inverse Drug Susceptibility Induced By Two Key Drug Resistance Proteins Of The Malaria Parasite.
Funder
National Health and Medical Research Council
Funding Amount
$567,273.00
Summary
The inexhaustible capacity of many pathogens and cancers to develop resistance to new drugs is a serious threat to world health. Yet in acquiring resistance to one drug, many pathogens and cancer cells become hypersensitive to one or more other drugs. We seek to elucidate several of the molecular mechanisms underpinning this phenomenon in the malaria parasite. Insights gained from this work will contribute to the formulation of new therapeutic strategies that overcome or retard drug resistance.
Targeting An Ion Pump In The Malaria Parasite With Multiple Compound Classes
Funder
National Health and Medical Research Council
Funding Amount
$384,686.00
Summary
Large-scale antimalarial drug screening projects have identified three different classes of compound that kill the malaria parasite at extremely low doses and which hold real promise as next-generation antimalarials. Genetic evidence, as well as preliminary data from our own lab, has led us to the hypothesis that all three compound classes exert their antimalarial effect by blocking a molecular ion pump on the parasite surface. The aim of this study is to test this.
Phenotypic Characterization Of Chloroquine Resistance In Plasmodia
Funder
National Health and Medical Research Council
Funding Amount
$585,473.00
Summary
In the Asia-Pacific region, vivax malaria is becoming the dominant species of infection. The emergence and spread of chloroquine resistant strains of P. vivax threatens malaria control and elimination efforts. This project aims to elucidate fundamental aspects of chloroquine resistance in non-falciparum malaria and identify novel therapeutic options. We will develop novel tests that will help national malaria control programs to monitor declining activity of standard anti-malarial drugs.
The Control And Regulatory Mechanisms Of Artemisinin Induced Dormancy In P. Falciparum
Funder
National Health and Medical Research Council
Funding Amount
$495,552.00
Summary
Malaria is a major global health problem and can only be reliably treated with artemisinin combinations in many areas due to widespread of drug resistance. However a proportion of parasites appear to be able to avoid the lethal effects of the drug by becoming “dormant” following exposure. They resume growth after the drug is wanned, a feature which is reminisent to cell cycle arrest. This study investigates the role of cell cycle machinery in dormancy following arteminsinin treatment.